A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
← catalyst calendarNCT02988960 · readout ≤ 42 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
163actual
Sites
22
Countries
Australia, Canada, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-02-22 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2016-12-12 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors Cancer
Interventions
- Drug: ABBV-927
- Drug: ABBV-927
- Drug: ABBV-181 — also filed as Budigalimab
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181
measured Up to 8 weeks
Time to Cmax (Tmax) of ABBV-927
measured Up to 12 weeks after participant's first dose
Maximum observed serum concentration (Cmax) of ABBV-927
measured Up to 12 weeks after participant's first dose
Terminal-Phase Elimination Rate Constant (β) of ABBV-927
measured Up to 12 weeks after participant's first dose
Terminal half-life (t1/2) of ABBV-927
measured Up to 4 weeks after participant's first dose
Area under the serum concentration-time curve (AUCt) of ABBV-927
measured Up to 12 weeks after participant's first dose
Time to Cmax (Tmax) of ABBV-181
measured Up to 12 weeks after participant's first dose
Maximum observed serum concentration (Cmax) of ABBV-181
measured Up to 12 weeks after participant's first dose
Terminal-Phase Elimination Rate Constant (β) of ABBV-181
measured Up to 12 weeks after participant's first dose
Terminal half-life (t1/2) of ABBV-181
measured Up to 4 weeks after participant's first dose
Area under the serum concentration-time curve (AUCt) of ABBV-181
measured Up to 12 weeks after participant's first dose
Number of Participants with Adverse Events
measured Up to 30 days after and up to 24-month of treatment period
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed